[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100304609":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":36,"responsibleParty":58,"collaborators":60,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":12,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":12,"enrollmentInfo":73,"targetDuration":12,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":12,"overallStatus":39,"whyStopped":12,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Thomas Jefferson University","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard of Care (Control Group)","NO_INTERVENTION","All participants in this group will receive the standard of care intervention provided by the RN.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Intervention Group","EXPERIMENTAL","In addition to the standard of care, the participants randomized to Intervention Group will be invited to a separate room. The following activities will be undertaken, in order to address patients' questions and concerns, and discuss potential solutions to their barriers to care\n\nThe patient will be asked to watch brief educational videos on \"Life with oral cancer treatment.\" The information contained in the videos will be reinforced with materials written at a 4th grade level, that correspond to each of the brief videos.The patient will receive a brief phone call (from the study coordinator) on the first business day following the baseline interview, and thereafter, two weeks following each visit to the oncology clinic.",[18],"Behavioral: Intervention",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"BEHAVIORAL","Intervention","All participants in this group will receive the standard of care intervention provided by the RN. This includes:Education in the clinic setting,Printed information about the chemotherapy drug and chemotherapy side effects. The RN will be blinded to the arm of study to which each patient is allocated.",[14],[26],{"name":27,"affiliation":5,"role":28},"Claudia M Dourado, MD","PRINCIPAL_INVESTIGATOR",[30,34],{"name":27,"role":31,"phone":32,"phoneExt":12,"email":33},"CONTACT","215-456-3880","Douradoc@einstein.edu",{"name":35,"role":31,"phone":32,"phoneExt":12,"email":33},"Claudia Dourado",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Albert Einstein Healthcare Network","RECRUITING","Philadelphia","Pennsylvania","19141","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-75.16362,39.95238,{"lat":49,"lon":48},[52,55],{"name":53,"role":31,"phone":32,"phoneExt":12,"email":54},"Claudia M Claudia M Dourado, MD","DouradoC@einstein.edu",{"name":56,"role":31,"phone":32,"phoneExt":12,"email":57},"John C Leighton, MD","leightoj@einstein.edu",{"type":59,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR",[61],{"name":62,"class":63},"Merck Sharp & Dohme LLC","INDUSTRY","100304609","assessment-of-multi-level-interventions-to-improve-adherence-to-oral-medications-in-cancer-patients-100304609",false,"NCT03245411","Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients","A Randomized, Controlled Trial to Assess Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients in a Socioeconomically Disadvantaged Community","Inclusion Criteria:\n\n* All patients on oral chemotherapeutic agents\n* Clinical diagnosis of stage IV breast cancer\n* Clinical diagnosis of stage III and IV colorectal cancer (not receiving concurrent radiation therapy)\n* Clinical diagnosis of stage IV non-small cell lung cancer\n* Clinical diagnosis of stage IV renal cell carcinoma\n* Clinical diagnosis of stage IV ovarian carcinoma\n* Clinical diagnosis of multiple myeloma\n* Clinical diagnosis of chronic myelogenous leukemia on TKI\n* Clinical diagnosis of myelodysplastic syndrome on Lenalidomide\n* Adjuvant treatment for Gastro Intestinal Stromal Tumor\n* Clinical diagnosis of chronic Lymphocytic Leukemia\n* Clinical diagnosis of metastatic Prostate cancer\n* Clinical diagnosis of hepatocellular Carcinoma\n* Clinical diagnosis of stage IV Melanoma\n* Clinical diagnosis of myelofibrosis\u002Fmyeloproliferative neoplasms\n* Age \\>18 years\n* ECOG Performance Status \\\u003C3\n\nExclusion Criteria:\n\n* ECOG Performance Status of 3 and above\n* Concurrent chemo radiation\n* Non-English speaker\n* Clinical diagnosis of dementia, or otherwise unable to give informed consent.\n* History of non-compliance (defined as the history of 2 or more missed appointments in the clinic).\n* Pregnant patients\n* Nursing Home Patients\n* Incarcerated","ALL","18 Years",{"count":74,"type":75},110,"ESTIMATED","INTERVENTIONAL",[78],"NA","Einstein Medical Center in Philadelphia serves a diverse group of the patient population. The majority of patients have a diverse cultural background, low literacy, and poor social-economic status. Medication adherence for chronic medical problems is in a range of 40-70%. Medication adherence among patients on oral anti-cancer therapy is not studied in detail. The main objective is to study medication adherence to oral anticancer agents in patients with low literacy and poor socio-economic status.",[81],"Cancer","2026-05-27",{"date":84,"type":85},"2026-05-29","ACTUAL",{"date":87,"type":85},"2017-07-20",{"date":89,"type":75},"2026-12-31",{"name":5,"class":6},1]